THE ANTIMALARIAL FERROQUINE: FROM BENCH TO CLINIC

被引：148

作者：

Biot, C. ^{[1
]}

Nosten, F. ^{[2
,3
,4
]}

Fraisse, L. ^{[5
]}

Ter-Minassian, D. ^{[6
]}

Khalife, J. ^{[7
]}

Dive, D. ^{[7
]}

机构：

[1] Univ Lille 1, Univ Lille Nord France, Unite Catalyse & Chim Solide, CNRS UMR 8181, F-59652 Villeneuve Dascq, France

[2] Shoklo Malaria Res Unit, Mae Sot Tak 63110, Thailand

[3] Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand

[4] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Nuffield Dept Clin Med, Oxford, England

[5] Sanofi Aventis, Ctr Toulouse, F-31036 Toulouse, France

[6] Sanofi Aventis Res & Dev, F-91385 Chilly Mazarin, France

[7] Univ Lille Nord France, CIIL, Inserm U1019, CNRS UMR 8024,Inst Pasteur Lille, F-59019 Lille, France

来源：

PARASITE | 2011年 / 18卷 / 03期

基金：

英国惠康基金;

关键词：

malaria; bioorganometallics; drug candidate; ferroquine; mechanism of action; resistance; IN-VITRO ACTIVITY; PLASMODIUM-FALCIPARUM; CHLOROQUINE; RESISTANCE; FERROCHLOROQUINE; FERROCENE; SUSCEPTIBILITY; METABOLITES; DERIVATIVES; MECHANISM;

D O I：

10.1051/parasite/2011183207

中图分类号：

R38 [医学寄生虫学]; Q [生物科学];

学科分类号：

090105 [作物生产系统与生态工程]; 100103 [病原生物学];

摘要：

Ferroquine (FQ, SSR97193) is currently the most advanced organometallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.

引用

页码：207 / 214

页数：8

共 44 条

[1]

The pathophysiology of vivax malaria [J].